Research programme: Diacylglycerol kinases inhibitors - Gossamer Bio
Latest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator Gossamer Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action DGKZ protein inhibitors; Diacylglycerol kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Nov 2022 Preclinical trials in Solid tumours in USA (unspecified route) before November 2022 (Gossamer Bio Pipeline, Apil 2023)
- 08 Nov 2022 Pharmacodynamics data from a preclinical study in Soild tumours presented at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC-2022) (Gossamer Bio Pipeline, April 2023)